Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Optimind Pharma Corp
C.OMND
Healthcare
Psychedelics
Optimind Pharma Corp. provides psychedelic therapies in Canada. The company offers psychedelic-like therapies for the treatment of post-traumatic stress syndrome, anxiety, depression, and other mental illnesses and disabilities through ketamine-assisted treatment and other psychedelic enhanced psychotherapy modalities. It also prescribes medical cannabis and other alternative treatments for various medical ailments through its clinics. Optimind Pharma Corp. is headquartered in Toronto, Canada.
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
New Post
CSE:OMND - Post by User
Optimind Pharma Corp
<< Previous
Bullboard Posts
Next >>
(401)
•••
TimeBuilder1
X
Post by
TimeBuilder1
on Mar 21, 2025 4:03pm
25 Views
Post# 36504357
HALTED !!!!!!!!!
HALTED !!!!!!!!!
.
<< Previous
Bullboard Posts
Next >>
Meeting the growing demand for healthier, "better for you" foods
Strengthening its position as Europe’s premier emerging tungsten player
Exploring new frontiers in digital asset investment
Aggressive drilling plans target gold and silver hotspots in Nevada
Viridian wraps drilling at Kraken Zone
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
{{ dialogTitle }}
×
Reject Reason
{{ policy.description }}
{{reasonError}}
Additional Comments
{{feedbackError}}
{{buttonTitle}}
Cancel
{{submitMsg}}
Featured News Links
Building Momentum in One of the World's Most Prospective Copper Regions
Sorrento Resources Provides Update on Exploration on Rodgers Cove Project, Newfoundland
A tungsten producer and developer in Portugal, South Korea & Spain on track to become a top supplier
Sego completes four drill holes at South Gold Zone, Cuba Zone deep hole underway
DiagnosTear Announces Clinical Study to Advance Analytical Validation & FDA Submission Pathway of TeaRx(TM)
A Company Focused on Developing Functional Healthier “Better For You” Foods
